Mandate

Vinge advises Cellartis AB

September 26, 2011

Vinge has advised the owners of Cellartis in connection with the sale of Cellartis AB to Cellectis S.A., a company listed on NYSE Euronext in Paris. The owners consist of InnovationsKapital among other venture capital investers as well as the company’s founders and employees. Cellartis has developed world-leading products based on pluripotent stem cells. Cellartis and Cellectis will jointly become a world-leading actor within R&D and development of products and services relating to regenerative and medical applications.

The purchase price consists of a cash element of € 16,400,000, and 1,930,000 in newly-issued Cellectis shares.

Vinge’s team primarily consisted of Anders Strid, Fredrik Sonander, Michael Sterner, Johanna Björnum Nyström, Emma Kero Ljungberg and Tove Bremell.

 
   

Related

Vinge advises Main Capital and Björn Lundén in connection with the acquisition of Aprello

Vinge has advised Björn Lundén, a provider of accounting and financial administration software, in connection with the acquisition of Aprello AB (“Aprello”). The strategic acquisition complements Björn Lundén’s growth strategy in the European financial administration software market.
January 30, 2025

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.
January 24, 2025

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in the divestment of shares in Marshall Group

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in connection with the divestment of shares in Marshall Group AB (publ) (”Marshall Group”) to HongShan Group, formerly known as Sequoia China. The Marshall Family will continue as owner in the Marshall Group.
January 24, 2025